Lorbrena (lorlatinib tablets) — Cigna
Non-Small Cell Lung Cancer – ROS1 Rearrangement-Positive
Initial criteria
- Patient age ≥ 18 years
- Patient has advanced or metastatic disease
- Patient has ROS1 rearrangement-positive disease
- Patient has tried at least one of Xalkori (crizotinib capsules), Zykadia (ceritinib capsules or tablets), or Rozlytrek (entrectinib capsules)
Approval duration
1 year